These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 17448812)

  • 1. Gastrointestinal safety of NSAIDs versus COX-2 inhibitors.
    Parashar A
    Lancet; 2007 Apr; 369(9570):1343-1344. PubMed ID: 17448812
    [No Abstract]   [Full Text] [Related]  

  • 2. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Laine L; Curtis SP; Cryer B; Kaur A; Cannon CP;
    Lancet; 2007 Feb; 369(9560):465-73. PubMed ID: 17292766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
    Hunt RH; Harper S; Watson DJ; Yu C; Quan H; Lee M; Evans JK; Oxenius B
    Am J Gastroenterol; 2003 Aug; 98(8):1725-33. PubMed ID: 12907325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis.
    Ramey DR; Watson DJ; Yu C; Bolognese JA; Curtis SP; Reicin AS
    Curr Med Res Opin; 2005 May; 21(5):715-22. PubMed ID: 15974563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [3 questions about gastrointestinal risk. Are coxibs here clearly better than NSAID?]].
    Krüger K
    MMW Fortschr Med; 2006 Nov; 148(48):12. PubMed ID: 17615761
    [No Abstract]   [Full Text] [Related]  

  • 6. The ever growing story of cyclo-oxygenase inhibition.
    Rodríguez LA; Patrignani P
    Lancet; 2006 Nov; 368(9549):1745-7. PubMed ID: 17113403
    [No Abstract]   [Full Text] [Related]  

  • 7. Global gastrointestinal safety profile of etoricoxib and lumiracoxib.
    Yuan Y; Hunt RH
    Curr Pharm Des; 2007; 13(22):2237-47. PubMed ID: 17691997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Celecoxib versus diclofenac and omeprazole to prevent recurrent ulcer bleeding.
    Lanas A
    N Engl J Med; 2003 Jun; 348(24):2464-6; author reply 2464-6. PubMed ID: 12802035
    [No Abstract]   [Full Text] [Related]  

  • 9. Perioperative blood loss and gastrointestinal tolerability of etoricoxib and diclofenac in total hip arthroplasty (ETO-DIC study): a single-center, prospective double-blinded randomized controlled trial.
    Winkler SH; Barta S; Kehl V; Schröter C; Wagner F; Grifka J; Springorum HR; Craiovan B
    Curr Med Res Opin; 2016; 32(1):37-47. PubMed ID: 26414653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [By what means does the rheumatic patient with gastrointestinal risks fare best?].
    Einecke D
    MMW Fortschr Med; 2007 Mar; 149(10):18. PubMed ID: 17408040
    [No Abstract]   [Full Text] [Related]  

  • 11. Are selective COX 2 inhibitors superior to traditional NSAIDs? Pharmacia's response to editorial.
    Geis GS
    BMJ; 2002 Jul; 325(7356):161; author reply 161. PubMed ID: 12134853
    [No Abstract]   [Full Text] [Related]  

  • 12. Upper gastrointestinal complications: the causes, consequences, and clinical outcomes.
    Am J Manag Care; 2001 Sep; 7(12 Suppl):S397-401. PubMed ID: 11570031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis.
    Hippisley-Cox J; Coupland C; Logan R
    BMJ; 2005 Dec; 331(7528):1310-6. PubMed ID: 16322018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclooxygenase (COX-2) selective inhibitors. Any better than NSAIDs?
    Nguyen A; Chaiton A
    Can Fam Physician; 2001 Jul; 47():1398-400. PubMed ID: 11494927
    [No Abstract]   [Full Text] [Related]  

  • 15. [Coronary risks with NSAID and coxibs. The end of hysteria].
    Einecke D
    MMW Fortschr Med; 2006 Nov; 148(48):10, 12. PubMed ID: 17615760
    [No Abstract]   [Full Text] [Related]  

  • 16. Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial.
    Baraf HS; Fuentealba C; Greenwald M; Brzezicki J; O'Brien K; Soffer B; Polis A; Bird S; Kaur A; Curtis SP;
    J Rheumatol; 2007 Feb; 34(2):408-20. PubMed ID: 17304660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Celecoxib and the CLASS trial].
    Englev E; Christensen KB
    Ugeskr Laeger; 2002 Oct; 164(41):4825-6. PubMed ID: 12407895
    [No Abstract]   [Full Text] [Related]  

  • 18. NSAID trials and the choice of comparators--questions of public health importance.
    Psaty BM; Weiss NS
    N Engl J Med; 2007 Jan; 356(4):328-30. PubMed ID: 17251528
    [No Abstract]   [Full Text] [Related]  

  • 19. Are selective COX 2 inhibitors superior to traditional NSAIDs? Both the CLASS and VIGOR trials support the COX 2 hypothesis.
    Stover RR
    BMJ; 2002 Jul; 325(7356):161; author reply 161. PubMed ID: 12134855
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy of the newest COX-2 selective inhibitors in rheumatic disease.
    Baraf HS
    Curr Pharm Des; 2007; 13(22):2228-36. PubMed ID: 17691996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.